資源描述：
《慢性心衰急性加重期應(yīng)用米力農(nóng)治療的臨床優(yōu)勢分析.doc》由會員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、慢性心衰急性加重期應(yīng)用米力農(nóng)治療的臨床優(yōu)勢分析［摘要］目的研究慢性心衰急性加重期應(yīng)用米力農(nóng)治療的臨床優(yōu)勢。方法研究對象：方便選取該院2013年4月一2015年2月收治的83例慢性心衰急性加重期患者。患者分組方法：抽簽法。83例患者分為常規(guī)組和試驗(yàn)組兩個(gè)組別。常規(guī)組常規(guī)方法治療；試驗(yàn)組在常規(guī)組基礎(chǔ)上加用米力農(nóng)治療。觀察指標(biāo)：①總有效率；②給藥前和給藥5d后患者左室射血分?jǐn)?shù)、左室舒張末內(nèi)徑、腦鈉肽、6min步行試驗(yàn)的差異。結(jié)果①試驗(yàn)組95.24%的總冇效率相比于常規(guī)組總冇效率75.61%更高，差異冇統(tǒng)計(jì)學(xué)意義，P0.05；給藥5d后試驗(yàn)組相比于常規(guī)組左室射血分?jǐn)?shù)
2、、左室舒張末內(nèi)徑、腦鈉肽>6min步行試驗(yàn)改善更顯著，其中，試驗(yàn)組分別為(36.18±5.71)%、(59.22±3.59)mm、(1825.58±423.26)ng/L>(310.18±46.71)m,常規(guī)組分別為(33?43±4.29)%、(60.11±4.94)mm、3117.28±531.12)ng/L>(220.43±56.29)m,差異冇統(tǒng)計(jì)學(xué)意義，P〈0?05。結(jié)論慢性心衰急性加重期應(yīng)用米力農(nóng)治療的臨床效果確切，可有效改善患者心功能，對患者預(yù)后冇益，值得推廣。［關(guān)鍵詞］慢性心衰；急性加重期；米力農(nóng)；臨床優(yōu)勢［中圖分類號］R54［文獻(xiàn)標(biāo)識碼］A［
3、文章編號］1674-0742(2016)08(a)-0133-03［Abstract］ObjectiveTheclinicalapplicationofmilrinoneinthetreatmentofthepredominantperiodofacuteexacerbationofchronicheartfailure.MethodsConvenientselection83casesofacuteexacerbationofchronicheartfailurewereadmittedinourhospitalfromApril2013toFebruar
4、y201583patientsweredividedintonormalgroupandexperimentalgrouptwogroups.Conventionalgrouproutinetreatment；Experimentalgrouponthebasisofconventionalgroupaddforcericefarming?Observationindexes：①thetotaleffectiverate；②drugdeliveryanddrugdeliveryin5daysbeforepatientswithleftventriculare
5、jectionfraction,leftventricularend~diastolicdiameter,brainnatriureticpeptide,thedifferencesbetweenthe6minuteswalktest?Results①theexperimentalgroupwas95.24%ofthetotalefficiencycomparedtotheconventionalgrouptotaleffectiverate75.61%higher,statisticallysignificantdifference,P0.05；after
6、5daysoftreatmentinexperimentalgroupcomparedtotheconventionalgroupofleftventricularejectionfractionandleftventricularenddiastolicdiameter,brainnatriureticpeptide,the6minutewalktestismoresignificantlyimproved,thetestgroupwere(36.18±5.71)%,(59.22±3.59)mm,1825.58±423.26)ng/L,(310.18±46
7、.71)mandcontrolgroupwere(33.43+4.29)%and(60.11+4.94)mm,(3117.28±531.12)ng/L,(220.43±56.29)m,thedifferencewasstatisticallysignificant,P[Keywords]Chronicheartfailure；Acuteexacerbationperiod；Mforcepeasants；Clinicaladvantages目前，隨著人口老齡化趨勢加重，各種心臟病發(fā)病率逐年升高，而慢性心衰為心臟病發(fā)展終末階段，患者死亡率高，多以出現(xiàn)心律失常、泵
8、衰竭和猝死為死亡原因。慢性心衰患者可在情緒激動、勞累
